Abstract
New molecular classification is one of the cornerstones of current and future progress in research and patient care for breast carcinoma. For the larger hormone-receptor positive and Her-2 negative subgroup, which concerns 75% of the patients, endocrine therapy and chemotherapy may be considered. Looking toward new-targeted therapies, this paper reviews the current use of these two treatment modalities in adjuvant, neoadjuvant and metastatic settings of this disease.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Hormonal / adverse effects
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Aromatase Inhibitors / adverse effects
-
Aromatase Inhibitors / therapeutic use*
-
Bevacizumab
-
Breast Neoplasms / chemistry
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / prevention & control
-
Chemotherapy, Adjuvant / methods
-
Drug Administration Schedule
-
Female
-
Gonadotropin-Releasing Hormone / agonists
-
Gonadotropin-Releasing Hormone / antagonists & inhibitors
-
Humans
-
Menopause
-
Neoplasm Proteins / metabolism
-
Neoplasm Recurrence, Local / prevention & control
-
Receptor, ErbB-2 / metabolism
-
Tamoxifen / adverse effects
-
Tamoxifen / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Hormonal
-
Aromatase Inhibitors
-
Neoplasm Proteins
-
Tamoxifen
-
Bevacizumab
-
Gonadotropin-Releasing Hormone
-
Receptor, ErbB-2